COMP <GO>
GH vs MRK // GROSS PROFIT MARGIN
Guardant Health Inc. (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: GH 4
— MRK 10
▲ GROSS PROFIT MARGIN LEADER: MRK
LAST: $178.80 (-3.51%) • MKT CAP: $24.87B
gross-margins
64.50%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
gross-margins
74.80%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GH VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GH | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 64.50% | 74.80% | -10.30 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -17.40% | 20.70% | -38.10 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -0.94% | 3.42% | -4.36 | MRK | /fcf-yield <GO> |
| Operating Margin | -44.50% | 34.30% | -78.80 | MRK | /operating-margins <GO> |
| Net Profit Margin | -42.40% | 28.10% | -70.50 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 32.90% | 1.30% | +31.60 | GH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.44 | 5.19 | +0.25 | GH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.50% | 6.60% | -0.10 | GH | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 57.3 | 56.9 | +0.39 | GH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.87 | 0.92 | -0.05 | MRK | /macro-sensitivity <GO> |
| Forward P/E Multiple | 19.0x | 18.4x | +0.60 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $24.87B | $361.02B | -$336.15B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GH REV | MRK REV | GH GROSS % | MRK GROSS % | GH FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $982.0M | $65.01B | 64.5% | 74.8% | -$233.1M | $12.36B |
| FY 2024 | $739.0M | $64.17B | 60.8% | 76.3% | -$274.9M | $18.10B |
| FY 2023 | $563.9M | $60.12B | 44.0% | 44.0% | -$350.4M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GH // BETA 0.87
MRK // BETA 0.92